Fresh analysis indicates that individuals who discontinue blockbuster weight-loss injections like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who end traditional lifestyle plans.
Findings released in a leading medical journal demonstrates that while obese individuals often shed about a fifth of their total mass while undergoing treatment, the mass comes back at an average rate of 0.8 kg per month upon discontinuation.
"People buying these medications need to be cognizant of the risk of rapid rebound weight gain when the therapy is stopped," stated lead investigator Dr. Susan Jebb.
That rate of recovery suggests a return to starting weight within about a year and a half.
Comparing Approaches
The analysis, which looked at 37 of trials involving thousands of patients, contrasted the outcomes of the injectable medications with conventional dieting.
Scientists note that people who shed pounds through lifestyle changes alone generally have a less rapid weight regain—approximately 0.1 kg a month—once they finish.
Explaining the Fast Regain
Doctors suggest the mode of action of the injections accounts for the amplified rebound.
GLP-1 drugs imitate a natural hormone called GLP-1, which helps regulate feelings of fullness.
"Artificially providing the hormone concentrations several times higher than the body's typical production may cause the system to produce less of its own natural hormone, and may also diminish sensitivity to its effects," noted Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this medication leads to appetite is no longer kept in check, making binge eating a significant risk."
A Chronic Disease?
Health authorities recommend the jabs for people with weight-linked medical conditions, alongside recommended lifestyle changes.
Professionals argue that, due to the high risk of relapse, the therapy should be considered life-long.
This perspective is echoed by drug manufacturers, who state that the results "emphasize the long-term nature of obesity," akin to managing conditions like diabetes.
Patient Accounts
Individuals who have stopped the jabs describe a intense resurgence of cravings.
"I experienced a switch activating and I was suddenly starving," recalled a patient.
The struggle is exacerbated if users have not developed sustainable lifestyle or habit changes during treatment.
Widespread Interest
Figures suggest that millions of people in the UK have used weight-loss jabs in the past year, with interest continuing to grow.
- Use is greater among females than men.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion access the medications through private healthcare rather than public health services.
Ultimately, clinicians emphasize that while GLP-1 drugs are powerful agents for weight loss, they are not a magic cure and long-term success relies on integrated lifestyle support.
